{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:00:20Z","timestamp":1792476020598,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008890","name":"University of Dundee","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008890","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Heart failure (HF) continues to be a serious public health challenge despite significant advancements in therapeutics and is often complicated by multiple other comorbidities. Of particular concern is type 2 diabetes mellitus (T2DM) which not only amplifies the risk, but also limits the treatment options available to patients. The sodium-glucose linked cotransporter subtype 2 (SGLT2)-inhibitor class, which was initially developed as a treatment for T2DM, has shown great promise in reducing cardiovascular risk, particularly around HF outcomes \u2013 regardless of diabetes status.<\/jats:p><jats:p>There are ongoing efforts to elucidate the true mechanism of action of this novel drug class. Its primary mechanism of inducing glycosuria and diuresis from receptor blockade in the renal nephron seems unlikely to be responsible for the rapid and striking benefits seen in clinical trials. Early mechanistic work around conventional therapeutic targets seem to be inconclusive. There are some emerging theories around its effect on myocardial energetics and calcium balance as well as on renal physiology. In this review, we discuss some of the cutting-edge hypotheses and concepts currently being explored around this drug class in an attempt better understand the molecular mechanics of this novel agent.<\/jats:p>","DOI":"10.1007\/s10741-020-10038-w","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T04:43:51Z","timestamp":1607057031000},"page":"623-642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["SGLT2-inhibitors; more than just glycosuria and diuresis"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-2566","authenticated-orcid":false,"given":"Amir","family":"Fathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2413-4770","authenticated-orcid":false,"given":"Keeran","family":"Vickneson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7358-9712","authenticated-orcid":false,"given":"Jagdeep S.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"issue":"3","key":"10038_CR1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","volume":"6","author":"PA Heidenreich","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC et al (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6(3):606\u2013619. https:\/\/doi.org\/10.1161\/HHF.0b013e318291329a","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10038_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/1479164112471064","volume":"10","author":"RM Cubbon","year":"2013","unstructured":"Cubbon RM, Adams B, Rajwani A, Mercer BN, Patel PA, Gherardi G et al (2013) Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diab Vasc Dis Res 10(4):330\u2013336. https:\/\/doi.org\/10.1177\/1479164112471064","journal-title":"Diab Vasc Dis Res"},{"issue":"12","key":"10038_CR3","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/eurjhf\/hfq160","volume":"12","author":"C Andersson","year":"2010","unstructured":"Andersson C, Norgaard ML, Hansen PR, Fosb\u00f8l EL, Schmiegelow M, Weeke P et al (2010) Heart failure severity, as determined by loop diuretic dosages, predicts the risk of developing diabetes after myocardial infarction: a nationwide cohort study. Eur J Heart Fail 12(12):1333\u20131338. https:\/\/doi.org\/10.1093\/eurjhf\/hfq160","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10038_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/s2213-8587(15)00044-3","volume":"3","author":"JA Udell","year":"2015","unstructured":"Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM (2015) Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 3(5):356\u2013366. https:\/\/doi.org\/10.1016\/s2213-8587(15)00044-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10038_CR5","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/ejhf.1146","volume":"20","author":"F Cosmi","year":"2018","unstructured":"Cosmi F, Shen L, Magnoli M, Abraham WT, Anand IS, Cleland JG et al (2018) Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. Eur J Heart Fail 20(5):888\u2013895. https:\/\/doi.org\/10.1002\/ejhf.1146","journal-title":"Eur J Heart Fail"},{"key":"10038_CR6","unstructured":"U.S. Food and Drug Administration. FDA approves new treatment for a type of heart failure. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-type-heart-failure. Accessed 10 June 2020"},{"issue":"1","key":"10038_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","volume":"261","author":"EM Wright","year":"2007","unstructured":"Wright EM, Hirayama BA, Loo DF et al (2007) Active sugar transport in health and disease. J Intern Med 261(1):32\u201343. https:\/\/doi.org\/10.1111\/j.1365-2796.2006.01746.x","journal-title":"J Intern Med"},{"key":"10038_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12933-016-0419-0","volume":"15","author":"JS Singh","year":"2016","unstructured":"Singh JS, Fathi A, Vickneson K, Mordi I, Mohan M, Houston JG et al (2016) Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol 15:97. https:\/\/doi.org\/10.1186\/s12933-016-0419-0","journal-title":"Cardiovasc Diabetol"},{"key":"10038_CR9","doi-asserted-by":"publisher","unstructured":"Mazidi M, Rezaie P, Gao HK, Kengne AP (2017) Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: A systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc 6(6). https:\/\/doi.org\/10.1161\/jaha.116.004007","DOI":"10.1161\/jaha.116.004007"},{"issue":"5","key":"10038_CR10","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","volume":"21","author":"T Toyama","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ et al (2019) Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab 21(5):1237\u20131250. https:\/\/doi.org\/10.1111\/dom.13648","journal-title":"Diabetes Obes Metab"},{"key":"10038_CR11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2147\/dddt.s50773","volume":"8","author":"MA Nauck","year":"2014","unstructured":"Nauck MA (2014) Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 8:1335\u20131380. https:\/\/doi.org\/10.2147\/dddt.s50773","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"10038_CR12","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R et al (2016) Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes 65(5):1190\u20131195. https:\/\/doi.org\/10.2337\/db15-1356","journal-title":"Diabetes"},{"issue":"4","key":"10038_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2337\/db19-0770","volume":"69","author":"M Alatrach","year":"2020","unstructured":"Alatrach M, Laichuthai N, Martinez R, Agyin C, Ali AM, Al-Jobori H et al (2020) Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors. Diabetes 69(4):681\u2013688. https:\/\/doi.org\/10.2337\/db19-0770","journal-title":"Diabetes"},{"issue":"9896","key":"10038_CR14","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/s0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J et al (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382(9896):941\u2013950. https:\/\/doi.org\/10.1016\/s0140-6736(13)60683-2","journal-title":"Lancet"},{"issue":"3","key":"10038_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","volume":"20","author":"KM Hallow","year":"2018","unstructured":"Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW (2018) Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 20(3):479\u2013487. https:\/\/doi.org\/10.1111\/dom.13126","journal-title":"Diabetes Obes Metab"},{"issue":"6s","key":"10038_CR16","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.amjmed.2017.04.009","volume":"130","author":"B Staels","year":"2017","unstructured":"Staels B (2017) Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. Am J Med 130(6s):S30\u2013S39. https:\/\/doi.org\/10.1016\/j.amjmed.2017.04.009","journal-title":"Am J Med"},{"key":"10038_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.120.048739","author":"NA Mordi","year":"2020","unstructured":"Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC et al (2020) Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial. Circulation. https:\/\/doi.org\/10.1161\/circulationaha.120.048739","journal-title":"Circulation"},{"issue":"22","key":"10038_CR18","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"11","key":"10038_CR19","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/circulationaha.118.037778","volume":"139","author":"D Fitchett","year":"2019","unstructured":"Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE et al (2019) Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation 139(11):1384\u20131395. https:\/\/doi.org\/10.1161\/circulationaha.118.037778","journal-title":"Circulation"},{"issue":"5","key":"10038_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/eurheartj\/ehx511","volume":"39","author":"D Fitchett","year":"2018","unstructured":"Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C et al (2018) Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial. Eur Heart J 39(5):363\u2013370. https:\/\/doi.org\/10.1093\/eurheartj\/ehx511","journal-title":"Eur Heart J"},{"issue":"2","key":"10038_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/circulationaha.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J et al (2018) Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation 137(2):119\u2013129. https:\/\/doi.org\/10.1161\/circulationaha.117.028268","journal-title":"Circulation"},{"issue":"7","key":"10038_CR22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"4","key":"10038_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"issue":"22","key":"10038_CR24","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/circulationaha.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM et al (2019) Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation 139(22):2528\u20132536. https:\/\/doi.org\/10.1161\/circulationaha.119.040130","journal-title":"Circulation"},{"issue":"10166","key":"10038_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0140-6736(18)32590-x","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31\u201339. https:\/\/doi.org\/10.1016\/s0140-6736(18)32590-x","journal-title":"Lancet"},{"issue":"23","key":"10038_CR26","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","volume":"71","author":"M Kosiborod","year":"2018","unstructured":"Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J et al (2018) Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. J Am Coll Cardiol 71(23):2628\u20132639. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.009","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10038_CR27","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1161\/circulationaha.118.039177","volume":"139","author":"E Patorno","year":"2019","unstructured":"Patorno E, Pawar A, Franklin JM, Najafzadeh M, D\u00e9ruaz-Luyet A, Brodovicz KG et al (2019) Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. Circulation 139(25):2822\u20132830. https:\/\/doi.org\/10.1161\/circulationaha.118.039177","journal-title":"Circulation"},{"key":"10038_CR28","unstructured":"Cannon C, McGuire D, Cherney D. Results of the eValuation of ERTugliflozin EffIcacy and Safety CardioVascular Outcomes Trial (Vertis CV). 80th American Diabetes Association Scientific Sessions; 2020 June 16. Online Symposium"},{"issue":"2","key":"10038_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V et al (2020) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41(2):255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486","journal-title":"Eur Heart J"},{"issue":"12","key":"10038_CR30","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G et al (2018) Management of Hyperglycemia in Type 2 Diabetes, 2018 A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41(12):2669\u20132701. https:\/\/doi.org\/10.2337\/dci18-0033","journal-title":"Diabetes Care"},{"issue":"21","key":"10038_CR31","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"10038_CR32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"10038_CR33","doi-asserted-by":"publisher","unstructured":"Singh JSS, Burrell LM, Cherif M, Squire IB, Clark AL, Lang CC et al (2017) Sacubitril\/valsartan: beyond natriuretic peptides. Heart 103(20):1569\u20131577. https:\/\/doi.org\/10.1136\/heartjnl-2017-311295","DOI":"10.1136\/heartjnl-2017-311295"},{"key":"10038_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz916","author":"JJV McMurray","year":"2020","unstructured":"McMurray JJV, Solomon SD, Docherty KF, Jhund PS et al (2020) The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehz916","journal-title":"Eur Heart J"},{"issue":"11","key":"10038_CR35","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/circresaha.119.313572","volume":"124","author":"MA Pfeffer","year":"2019","unstructured":"Pfeffer MA, Shah AM, Borlaug BA (2019) Heart Failure With Preserved Ejection Fraction In Perspective. Circ Res 124(11):1598\u20131617. https:\/\/doi.org\/10.1161\/circresaha.119.313572","journal-title":"Circ Res"},{"issue":"19","key":"10038_CR36","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJMoa032566","volume":"350","author":"MR Zile","year":"2004","unstructured":"Zile MR, Baicu CF, Gaasch WH et al (2004) Diastolic heart failure\u2013abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350(19):1953\u20131959. https:\/\/doi.org\/10.1056\/NEJMoa032566","journal-title":"N Engl J Med"},{"issue":"9386","key":"10038_CR37","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/s0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386):777\u2013781. https:\/\/doi.org\/10.1016\/s0140-6736(03)14285-7","journal-title":"Lancet"},{"issue":"23","key":"10038_CR38","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359(23):2456\u20132467. https:\/\/doi.org\/10.1056\/NEJMoa0805450","journal-title":"N Engl J Med"},{"issue":"19","key":"10038_CR39","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JG Cleland","year":"2006","unstructured":"Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338\u20132345. https:\/\/doi.org\/10.1093\/eurheartj\/ehl250","journal-title":"Eur Heart J"},{"issue":"15","key":"10038_CR40","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1313731","journal-title":"N Engl J Med"},{"issue":"17","key":"10038_CR41","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al (2019) Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 381(17):1609\u20131620. https:\/\/doi.org\/10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"issue":"30","key":"10038_CR42","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","volume":"39","author":"CSP Lam","year":"2018","unstructured":"Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ et al (2018) Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J 39(30):2780\u20132792. https:\/\/doi.org\/10.1093\/eurheartj\/ehy301","journal-title":"Eur Heart J"},{"issue":"19","key":"10038_CR43","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","volume":"52","author":"C Ronco","year":"2008","unstructured":"Ronco C, Haapio M, House AA, Anavekar N, Bellomo R et al (2008) Cardiorenal syndrome. J Am Coll Cardiol 52(19):1527\u20131539. https:\/\/doi.org\/10.1016\/j.jacc.2008.07.051","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10038_CR44","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1161\/circulationaha.105.580506","volume":"113","author":"HL Hillege","year":"2006","unstructured":"Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S et al (2006) Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113(5):671\u2013678. https:\/\/doi.org\/10.1161\/circulationaha.105.580506","journal-title":"Circulation"},{"issue":"6","key":"10038_CR45","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cardfail.2007.03.011","volume":"13","author":"JT Heywood","year":"2007","unstructured":"Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J et al (2007) High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 13(6):422\u2013430. https:\/\/doi.org\/10.1016\/j.cardfail.2007.03.011","journal-title":"J Card Fail"},{"issue":"5","key":"10038_CR46","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jcjd.2014.05.006","volume":"38","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA (2014) Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection? Can J Diabetes 38(5):356\u2013363. https:\/\/doi.org\/10.1016\/j.jcjd.2014.05.006","journal-title":"Can J Diabetes"},{"issue":"Suppl 2","key":"10038_CR47","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.2337\/dcS15-3006","volume":"39","author":"P Fioretto","year":"2016","unstructured":"Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R et al (2016) SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care 39(Suppl 2):S165\u2013S171. https:\/\/doi.org\/10.2337\/dcS15-3006","journal-title":"Diabetes Care"},{"issue":"6","key":"10038_CR48","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s00125-020-05133-4","volume":"63","author":"DZI Cherney","year":"2020","unstructured":"Cherney DZI, Heerspink HJL, Frederich R, Maldonado M, Liu J, Pong A et al (2020) Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia 63(6):1128\u20131140. https:\/\/doi.org\/10.1007\/s00125-020-05133-4","journal-title":"Diabetologia"},{"issue":"6823","key":"10038_CR49","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/bmj.304.6823.339","volume":"304","author":"S Bj\u00f6rck","year":"1992","unstructured":"Bj\u00f6rck S, Mulec H, Johnsen SA, Nord\u00e9n G, Aurell M et al (1992) Renal protective effect of enalapril in diabetic nephropathy. BMJ 304(6823):339\u2013343. https:\/\/doi.org\/10.1136\/bmj.304.6823.339","journal-title":"BMJ"},{"issue":"19","key":"10038_CR50","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1056\/NEJMoa042274","volume":"351","author":"AH Barnett","year":"2004","unstructured":"Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J et al (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351(19):1952\u20131961. https:\/\/doi.org\/10.1056\/NEJMoa042274","journal-title":"N Engl J Med"},{"issue":"20","key":"10038_CR51","doi-asserted-by":"publisher","first-page":"e013389","DOI":"10.1161\/jaha.119.013389","volume":"8","author":"CSP Lam","year":"2019","unstructured":"Lam CSP, Chandramouli C, Ahooja V, Verma S et al (2019) SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. J Am Heart Assoc 8(20):e013389. https:\/\/doi.org\/10.1161\/jaha.119.013389","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"10038_CR52","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"10038_CR53","unstructured":"European Society of Cardiology. DAPA-CKD trial meets primary endpoint in patients with chronic kidney disease. https:\/\/www.escardio.org\/The-ESC\/Press-Office\/Press-releases\/DAPA. Accessed 09 Sep 2020"},{"issue":"20","key":"10038_CR54","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF et al (2017) Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol 70(20):2476\u20132486. https:\/\/doi.org\/10.1016\/j.jacc.2017.08.074","journal-title":"J Am Coll Cardiol"},{"key":"10038_CR55","unstructured":"Johnson & Johnson. U.S. FDA Approves INVOKANA\u00ae (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD. https:\/\/www.jnj.com\/u-s-fda-approves-invokana-canagliflozin-to-treat-diabetic-kidney-disease-dkd-and-reduce-the-risk-of-hospitalization-for-heart-failure-in-patients-with-type-2-diabetes-t2d-and-dkd. Accessed 18 June 2020"},{"key":"10038_CR56","unstructured":"AstraZenaca. FDA grants Fast Track designation for Farxiga in chronic kidney disease. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/fda-grants-fast-track-designation-for-farxiga-in-chronic-kidney-disease-27082019.html#:~:text=AstraZeneca%20today%20announced%20that%20the,chronic%20kidney%20disease%20(CKD). Accessed 09 Sep 2020"},{"issue":"5","key":"10038_CR57","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","volume":"56","author":"DG Kramer","year":"2010","unstructured":"Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE et al (2010) Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 56(5):392\u2013406. https:\/\/doi.org\/10.1016\/j.jacc.2010.05.011","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10038_CR58","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/S0735-1097(00)01006-8","volume":"36","author":"BA Groenning","year":"2000","unstructured":"Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR et al (2000) Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 36(7):2072\u20132080","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10038_CR59","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/s0735-1097(02)01965-4","volume":"40","author":"M Cicoira","year":"2002","unstructured":"Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G et al (2002) Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 40(2):304\u2013310. https:\/\/doi.org\/10.1016\/s0735-1097(02)01965-4","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10038_CR60","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1161\/01.cir.91.10.2573","volume":"91","author":"B Greenberg","year":"1995","unstructured":"Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C et al (1995) Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction Results of the SOLVD echocardiography substudy. Circulation 91(10):2573\u20132581. https:\/\/doi.org\/10.1161\/01.cir.91.10.2573","journal-title":"Circulation"},{"issue":"6","key":"10038_CR61","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.2337\/dc19-2187","volume":"43","author":"JSS Singh","year":"2020","unstructured":"Singh JSS, Mordi IR, Vickneson K, Fathi A, Donnan PT, Mohan M et al (2020) Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. Diabetes Care 43(6):1356\u20131359. https:\/\/doi.org\/10.2337\/dc19-2187","journal-title":"Diabetes Care"},{"issue":"18","key":"10038_CR62","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/circulationaha.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE et al (2019) Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation 140(18):1463\u20131476. https:\/\/doi.org\/10.1161\/circulationaha.119.042929","journal-title":"Circulation"},{"key":"10038_CR63","unstructured":"Singh JSS, Mordi I, Fathi A, Vickneson K, Donnan PT, Mohan M et al (2018) P905 Research into the effect of sodium-glucose linked transporter inhibition in left ventricular remodelling in patients with heart failure and diabetes mellitus. European Heart J 39(suppl_1). https:\/\/doi.org\/10.1093\/eurheartj\/ehy564.P9055"},{"issue":"21","key":"10038_CR64","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/circulationaha.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H et al (2019) Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation 140(21):1693\u20131702. https:\/\/doi.org\/10.1161\/circulationaha.119.042375","journal-title":"Circulation"},{"key":"10038_CR65","unstructured":"NCT03619213. Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03619213. Accessed 10 July 2020"},{"key":"10038_CR66","unstructured":"NCT03057951. Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057951. Accessed 10 July 2020"},{"key":"10038_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa419","author":"AJM Brown","year":"2020","unstructured":"Brown AJM, Gandy S, McCrimmon R, Houston JG, Struthers AD, Lang CC et al (2020) A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa419","journal-title":"Eur Heart J"},{"key":"10038_CR68","unstructured":"NCT03485222.\u00a0Are the \"Cardiac Benefits\" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4). (EMPA-TROPISM). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03485222. Accessed 10 July 2020"},{"key":"10038_CR69","unstructured":"NCT03036150.\u00a0A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03036150. Accessed 10 July 2020"},{"key":"10038_CR70","unstructured":"NCT03594110.\u00a0EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03594110. Accessed 10 July 2020"},{"issue":"1","key":"10038_CR71","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1172\/jci58227","volume":"122","author":"SA Goonasekera","year":"2012","unstructured":"Goonasekera SA, Hammer K, Auger-Messier M, Bodi I, Chen X, Zhang H et al (2012) Decreased cardiac L-type Ca2+ channel activity induces hypertrophy and heart failure in mice. J Clin Invest 122(1):280\u2013290. https:\/\/doi.org\/10.1172\/jci58227","journal-title":"J Clin Invest"},{"issue":"1","key":"10038_CR72","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12551-014-0152-4","volume":"7","author":"K Walweel","year":"2015","unstructured":"Walweel K, Laver DR (2015) Mechanisms of SR calcium release in healthy and failing human hearts. Biophys Rev 7(1):33\u201341. https:\/\/doi.org\/10.1007\/s12551-014-0152-4","journal-title":"Biophys Rev"},{"issue":"2","key":"10038_CR73","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/s0008-6363(97)00277-0","volume":"37","author":"G Hasenfuss","year":"1998","unstructured":"Hasenfuss G (1998) Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res 37(2):279\u2013289. https:\/\/doi.org\/10.1016\/s0008-6363(97)00277-0","journal-title":"Cardiovasc Res"},{"issue":"4","key":"10038_CR74","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/s0008-6363(02)00809-x","volume":"57","author":"A Baartscheer","year":"2003","unstructured":"Baartscheer A, Schumacher CA, van Borren MMGJ, Belterman CNW, Coronel R, Fiolet JWT et al (2003) Increased Na+\/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res 57(4):1015\u20131024. https:\/\/doi.org\/10.1016\/s0008-6363(02)00809-x","journal-title":"Cardiovasc Res"},{"key":"10038_CR75","doi-asserted-by":"publisher","unstructured":"Lambert R, Srodulski S, Peng X, Margulies KB, Despa F, Despa S (2015) Intracellular Na+ concentration ([Na+]i) is elevated in diabetic hearts due to enhanced Na+\u2013glucose cotransport. J Am Heart Assoc 4(9). https:\/\/doi.org\/10.1161\/jaha.115.002183","DOI":"10.1161\/jaha.115.002183"},{"key":"10038_CR76","doi-asserted-by":"publisher","unstructured":"Bay J, Kohlhaas M, Maack C et al (2013) Intracellular Na+ and cardiac metabolism. J Mol Cell Cardiol 61:20\u201327. https:\/\/doi.org\/10.1016\/j.yjmcc.2013.05.010","DOI":"10.1016\/j.yjmcc.2013.05.010"},{"key":"10038_CR77","doi-asserted-by":"publisher","unstructured":"Uthman L, Baartscheer A, Schumacher CA, Fiolet JWT, Kuschma MC, Hollmann MW et al (2018) Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front Physiol 9.\u00a0https:\/\/doi.org\/10.3389\/fphys.2018.01575","DOI":"10.3389\/fphys.2018.01575"},{"issue":"2","key":"10038_CR78","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DD, Hirayama BA et al (2011) Biology of human sodium glucose transporters. Physiol Rev 91(2):733\u2013794. https:\/\/doi.org\/10.1152\/physrev.00055.2009","journal-title":"Physiol Rev"},{"issue":"3","key":"10038_CR79","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","volume":"31","author":"N Hammoudi","year":"2017","unstructured":"Hammoudi N, Jeong D, Singh R, Farhat A, Komajda M, Mayoux E et al (2017) Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes. Cardiovasc Drugs Ther 31(3):233\u2013246. https:\/\/doi.org\/10.1007\/s10557-017-6734-1","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"10038_CR80","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ehf2.12336","volume":"5","author":"J Mustroph","year":"2018","unstructured":"Mustroph J, Wagemann O, L\u00fccht CM, Trum M, Hammer KP, Sag CM et al (2018) Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail 5(4):642\u2013648. https:\/\/doi.org\/10.1002\/ehf2.12336","journal-title":"ESC Heart Fail"},{"key":"10038_CR81","doi-asserted-by":"publisher","unstructured":"Lee TI, Chen YC, Lin YK, Chung CC, Lu YY, Kao YH et al (2019) Empagliflozin attenuates myocardial sodium and calcium dysregulation and reverses cardiac remodeling in streptozotocin-induced diabetic rats. Int J Mol Sci 20(7). https:\/\/doi.org\/10.3390\/ijms20071680","DOI":"10.3390\/ijms20071680"},{"key":"10038_CR82","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3389\/fphys.2017.01077","volume":"8","author":"I Andreadou","year":"2017","unstructured":"Andreadou I, Efentakis P, Balafas E, Togliatto G, Davos CH, Varela A et al (2017) Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects. Front Physiol 8:1077. https:\/\/doi.org\/10.3389\/fphys.2017.01077","journal-title":"Front Physiol"},{"issue":"3","key":"10038_CR83","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A et al (2018) Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia 61(3):722\u2013726. https:\/\/doi.org\/10.1007\/s00125-017-4509-7","journal-title":"Diabetologia"},{"issue":"11","key":"10038_CR84","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cvr\/cvz037","volume":"115","author":"Z Li","year":"2019","unstructured":"Li Z, Agrawal V, Ramratnam M, Sharma RK, D\u2019Auria S, Sincoular A et al (2019) Cardiac sodium-dependent glucose cotransporter 1 is a novel mediator of ischaemia\/reperfusion injury. Cardiovasc Res 115(11):1646\u20131658. https:\/\/doi.org\/10.1093\/cvr\/cvz037","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10038_CR85","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, W\u00fcst RCI, Fiolet JWT, Stienen GJM, Coronel R et al (2017) Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits. Diabetologia 60(3):568\u2013573. https:\/\/doi.org\/10.1007\/s00125-016-4134-x","journal-title":"Diabetologia"},{"issue":"6","key":"10038_CR86","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1161\/circresaha.113.300376","volume":"113","author":"T Doenst","year":"2013","unstructured":"Doenst T, Nguyen TD, Abel ED (2013) Cardiac Metabolism in Heart Failure - Implications beyond ATP production. Circ Res 113(6):709\u2013724. https:\/\/doi.org\/10.1161\/circresaha.113.300376","journal-title":"Circ Res"},{"issue":"3","key":"10038_CR87","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","volume":"85","author":"WC Stanley","year":"2005","unstructured":"Stanley WC, Recchia FA, Lopaschuk GD (2005) Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85(3):1093\u20131129. https:\/\/doi.org\/10.1152\/physrev.00006.2004","journal-title":"Physiol Rev"},{"issue":"7","key":"10038_CR88","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR et al (2016) Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis Diabetes Care 39(7):1115\u20131122. https:\/\/doi.org\/10.2337\/dc16-0542","journal-title":"A Unifying Hypothesis Diabetes Care"},{"issue":"15","key":"10038_CR89","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B et al (2019) Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. J Am Coll Cardiol 73(15):1931\u20131944. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.056","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10038_CR90","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jacbts.2016.11.009","volume":"2","author":"AR Wende","year":"2017","unstructured":"Wende AR, Brahma MK, McGinnis GR, Young ME et al (2017) Metabolic Origins of Heart Failure. JACC Basic Transl Sci 2(3):297\u2013310. https:\/\/doi.org\/10.1016\/j.jacbts.2016.11.009","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"10038_CR91","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.hlc.2008.11.003","volume":"18","author":"RH Ritchie","year":"2009","unstructured":"Ritchie RH (2009) Evidence for a causal role of oxidative stress in the myocardial complications of insulin resistance. Heart Lung Circ 18(1):11\u201318. https:\/\/doi.org\/10.1016\/j.hlc.2008.11.003","journal-title":"Heart Lung Circ"},{"issue":"10","key":"10038_CR92","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41580-018-0044-8","volume":"19","author":"Q Yang","year":"2018","unstructured":"Yang Q, Vijayakumar A, Kahn BB (2018) Metabolites as regulators of insulin sensitivity and metabolism. Nat Rev Mol Cell Biol 19(10):654\u2013672. https:\/\/doi.org\/10.1038\/s41580-018-0044-8","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10038_CR93","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1475-2840-11-63","volume":"11","author":"L Aerni-Flessner","year":"2012","unstructured":"Aerni-Flessner L, Abi-Jaoude M, Koenig A, Payne M, Hruz PW et al (2012) GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle. Cardiovasc Diabetol 11:63. https:\/\/doi.org\/10.1186\/1475-2840-11-63","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10038_CR94","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.2337\/dc15-0642","volume":"38","author":"S Mudaliar","year":"2015","unstructured":"Mudaliar S, Polidori D, Zambrowicz B, Henry RR et al (2015) Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside. Diabetes Care 38(12):2344\u20132353. https:\/\/doi.org\/10.2337\/dc15-0642","journal-title":"Diabetes Care"},{"issue":"18","key":"10038_CR95","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1161\/circulationaha.118.036459","volume":"139","author":"R Nielsen","year":"2019","unstructured":"Nielsen R, M\u00f8ller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J et al (2019) Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation 139(18):2129\u20132141. https:\/\/doi.org\/10.1161\/circulationaha.118.036459","journal-title":"Circulation"},{"issue":"1","key":"10038_CR96","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/03009734.2018.1515281","volume":"124","author":"A \u00c5kerblom","year":"2019","unstructured":"\u00c5kerblom A, Oldgren J, Latva-Rasku A, Johansson L, Lisovskaja V, Karlsson C et al (2019) Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients-a description of the DAPACARD study. Ups J Med Sci 124(1):59\u201364. https:\/\/doi.org\/10.1080\/03009734.2018.1515281","journal-title":"Ups J Med Sci"},{"issue":"9733","key":"10038_CR97","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/s0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A, Bastien A, List JF et al (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375(9733):2223\u20132233. https:\/\/doi.org\/10.1016\/s0140-6736(10)60407-2","journal-title":"Lancet"},{"issue":"17","key":"10038_CR98","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/circulationaha.118.038881","volume":"139","author":"M Sano","year":"2019","unstructured":"Sano M, Goto S (2019) Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. Circulation 139(17):1985\u20131987. https:\/\/doi.org\/10.1161\/circulationaha.118.038881","journal-title":"Circulation"},{"issue":"9","key":"10038_CR99","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J et al (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15(9):853\u2013862. https:\/\/doi.org\/10.1111\/dom.12127","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10038_CR100","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/circulationaha.119.044235","volume":"141","author":"CD Mazer","year":"2020","unstructured":"Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A et al (2020) Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation 141(8):704\u2013707. https:\/\/doi.org\/10.1161\/circulationaha.119.044235","journal-title":"Circulation"},{"issue":"1","key":"10038_CR101","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4331\/wjbc.v7.i1.44","volume":"7","author":"L Morla","year":"2016","unstructured":"Morla L, Edwards A, Crambert G et al (2016) New insights into sodium transport regulation in the distal nephron: Role of G-protein coupled receptors. World J Biol Chem 7(1):44\u201363. https:\/\/doi.org\/10.4331\/wjbc.v7.i1.44","journal-title":"World J Biol Chem"},{"issue":"4","key":"10038_CR102","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1042\/cs20070229","volume":"114","author":"J Piuhola","year":"2008","unstructured":"Piuhola J, Kerkel\u00e4 R, Keenan JI, Hampton MB, Richards AM, Pemberton CJ (2008) Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia\/reperfusion injury. Clin Sci (Lond) 114(4):293\u2013304. https:\/\/doi.org\/10.1042\/cs20070229","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"10038_CR103","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ehj.2003.11.017","volume":"25","author":"P van der Meer","year":"2004","unstructured":"van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ et al (2004) Erythropoietin in cardiovascular diseases. Eur Heart J 25(4):285\u2013291. https:\/\/doi.org\/10.1016\/j.ehj.2003.11.017","journal-title":"Eur Heart J"},{"issue":"2","key":"10038_CR104","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijcard.2013.12.011","volume":"171","author":"F Sanchis-Gomar","year":"2014","unstructured":"Sanchis-Gomar F, Garcia-Gimenez JL, Pareja-Galeano H, Romagnoli M, Perez-Quilis C, Lippi G et al (2014) Erythropoietin and the heart: physiological effects and the therapeutic perspective. Int J Cardiol 171(2):116\u2013125. https:\/\/doi.org\/10.1016\/j.ijcard.2013.12.011","journal-title":"Int J Cardiol"},{"issue":"13","key":"10038_CR105","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","volume":"368","author":"K Swedberg","year":"2013","unstructured":"Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R et al (2013) Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368(13):1210\u20131219. https:\/\/doi.org\/10.1056\/NEJMoa1214865","journal-title":"N Engl J Med"},{"issue":"5","key":"10038_CR106","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/s2213-8587(16)00052-8","volume":"4","author":"JH Wu","year":"2016","unstructured":"Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundstr\u00f6m J et al (2016) Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 4(5):411\u2013419. https:\/\/doi.org\/10.1016\/s2213-8587(16)00052-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10038_CR107","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1111\/dom.13299","volume":"20","author":"M Kosiborod","year":"2018","unstructured":"Kosiborod M, Birkeland KI, Cavender MA, Fu AZ, Wilding JP, Khunti K et al (2018) Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. Diabetes Obes Metab 20(8):1983\u20131987. https:\/\/doi.org\/10.1111\/dom.13299","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10038_CR108","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M et al (2018) How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 41(2):356\u2013363. https:\/\/doi.org\/10.2337\/dc17-1096","journal-title":"Diabetes Care"},{"issue":"11","key":"10038_CR109","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1161\/circresaha.114.302589","volume":"114","author":"VG Florea","year":"2014","unstructured":"Florea VG, Cohn JN (2014) The autonomic nervous system and heart failure. Circ Res 114(11):1815\u20131826. https:\/\/doi.org\/10.1161\/circresaha.114.302589","journal-title":"Circ Res"},{"issue":"1\u20132","key":"10038_CR110","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1081\/ceh-100001196","volume":"23","author":"PC Perin","year":"2001","unstructured":"Perin PC, Maule S, Quadri R et al (2001) Sympathetic nervous system, diabetes, and hypertension. Clin Exp Hypertens 23(1\u20132):45\u201355. https:\/\/doi.org\/10.1081\/ceh-100001196","journal-title":"Clin Exp Hypertens"},{"issue":"2","key":"10038_CR111","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","volume":"5","author":"LY Herat","year":"2020","unstructured":"Herat LY, Magno AL, Rudnicka C, Hricova J, Carnagarin R, Ward NC et al (2020) SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection. JACC Basic Transl Sci 5(2):169\u2013179. https:\/\/doi.org\/10.1016\/j.jacbts.2019.11.007","journal-title":"JACC Basic Transl Sci"},{"issue":"19","key":"10038_CR112","doi-asserted-by":"publisher","first-page":"8030","DOI":"10.1073\/pnas.1016088108","volume":"108","author":"I Kimura","year":"2011","unstructured":"Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, Miyauchi S et al (2011) Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A 108(19):8030\u20138035. https:\/\/doi.org\/10.1073\/pnas.1016088108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10038_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2012.10.002","volume":"1","author":"E Braunwald","year":"2013","unstructured":"Braunwald E (2013) Heart failure. JACC Heart Fail 1(1):1\u201320. https:\/\/doi.org\/10.1016\/j.jchf.2012.10.002","journal-title":"JACC Heart Fail"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-10038-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-020-10038-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-10038-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T06:11:42Z","timestamp":1617689502000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-020-10038-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":113,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10038"],"URL":"https:\/\/doi.org\/10.1007\/s10741-020-10038-w","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]},"assertion":[{"value":"5 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JSS has received financial and non-financial support from Boehringer Ingelheim, Astra Zeneca and Merck Sharp and Dohme for work that is relevant but unrelated to this article. AF and KV report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}